Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

GBIO - Generation Bio Co.


IEX Last Trade
1.06
-0.045   -4.245%

Share volume: 1,196
Last Updated: Fri 27 Dec 2024 05:29:53 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): -0.39%

PREVIOUS CLOSE
CHG
CHG%

$1.10
-0.05
-4.07%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-2.73%
1 Month
-25.69%
3 Months
-53.88%
6 Months
-61.79%
1 Year
-42.16%
2 Year
-74.58%
Key data
Stock price
$1.06
P/E Ratio 
0.00
DAY RANGE
$1.09 - $1.10
EPS 
$0.00
52 WEEK RANGE
$1.10 - $4.65
52 WEEK CHANGE
-$41.21
MARKET CAP 
176.197 M
YIELD 
N/A
SHARES OUTSTANDING 
66.741 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
3.44
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$722,461
AVERAGE 30 VOLUME 
$421,453
Company detail
CEO: Cameron G. McDonough
Region: US
Website: generationbio.com
Employees: 150
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Generation Bio Co. develops therapies for the treatment of rare and prevalent diseases. The company was formerly known as Torus Therapeutics, Inc. It focuses on the diseases of skeletal muscle, central nervous system, and oncology.

Recent news